Zimmer Wins FDA Clearance for iASSIST; NuPathe's Upcoming PDUFA Decision Print E-mail
By Staff and Wire Reports   
Thursday, 17 January 2013 20:28
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 17, 2013.

Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH)
, a global leader in musculoskeletal health, announced it has received 510(k) clearance from the U.S. FDA to market iASSIST™ Knee, the Personalized Guidance System™ for knee replacement procedures.

iASSIST represents a revolutionary next step in surgical guidance, providing simple, intuitive and accurate intraoperative feedback and alignment validation to surgeons during joint replacement procedures, eliminating the need for bulky capital equipment.  Current robotic and navigation systems use optical-tracking, requiring a clear line-of-sight into the surgical field, and rely upon complex additional equipment in the operating room, providing feedback on external computer screens.


NuPathe Inc. (NASDAQ:PATH)
is a biotechnology company focused on central nervous system disorders, including neurological and psychiatric disorders. With a PDUFA date coming up on January 17, 2013, for its Zecuity migraine patch, many traders and investors are closely watching the stock, as an approval could send shares sharply higher over the short-term.

Migraines affect approximately 30 million adults in the U.S., with crippling pain that all too often goes untreated. Existing medications like oral triptans are ineffective for approximately eight million U.S. adults that experience MRN (nausea) in more than half of their migraines, since the nausea causes them to either avoid or delay taking oral treatments.

Also Thursday:

Alimera Sciences, Inc., (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

AtheroNova Inc. (OTCBB: AHRO)
, a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that its CEO, Thomas W. Gardner, will present at "NINE"; Noble Financial Capital Markets' Ninth Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Wednesday, January 23rd at 11:00 am Eastern Time.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public.

Boston Scientific Corporation (NYSE: BSX)
will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31st, 2012 on Tuesday, January 29th, at 8:00 a.m. ET.

today announced two new connected health offerings designed to meet an increasing need in the healthcare industry for software and services that helps enable efficient, convenient, high-quality patient care, and more collaboration across the healthcare continuum.

Ecology and Environment, Inc. (E & E) (NASDAQ: EEI)
has been awarded approximately $39 million in contracts to consult on the development of eco-cities and a large health care complex for the China International Finance and Guarantee Group with the backing of the Chinese government.

Generex Biotechnology Corporation (OTCBB: GNBT)
today announced that the AE37 breast cancer vaccine under development by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been featured in a Micro-Cap Review interview of Antigen Express President Dr. Eric von Hofe, PhD conducted earlier this month at the JPMorgan Healthcare Conference in San Francisco.

Given Imaging Ltd (NASDAQ: GIVN)
, a world leader in GI medical devices and pioneer of capsule endoscopy, today announced that effective January 1, 2013, the 2013 National Average Medicare Physician Fee allowable for its recently acquired SmartPill® Wireless Motility Capsule (SmartPill) procedure is $1,188.93.

Ingen Technologies, Inc. (PINKSHEETS: IGNT)
, an emerging medical device manufacturer with patented proprietary medical technology for the growing $55 Billion US home healthcare industry, is pleased to announce that the company is making preparations for manufacturing large quantities of its products while its Quebec-Canada export distributor, MMT Inc., has verbal commitments of approximately $3 Million in product purchases for this month.

La Jolla Pharmaceutical Company (OTCQB: LJPC)
("La Jolla" and "Company"), a leader in the development of therapeutics that target galectin-3, announced today that George F. Tidmarsh, MD, PhD, President and Chief Executive Officer, will be presenting at "The World MoneyShow" on January 31, 2013 at 3:00 PM eastern time.

Life Technologies Corporation (NASDAQ: LIFE)
today announced it will report its fourth quarter and fiscal year 2012 financial results on Monday, Feb. 4 after market close.

Medicago Inc. (TSX: MDG; OTCQX: MDCGF)
, a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the execution of $15,000,000 loan agreement with a major Pharmaceutical company.

Merus Labs International Inc. (TSX:MSL) (NASDAQ:MSLI) is pleased to announce that through its wholly owned subsidiaries, Merus Labs B.V and Merus Labs Luxco S.à R.L., it has entered into promotion and distribution agreements with selected partners in certain European countries for the Company's Emselex®/Enablex® product. Emselex®/Enablex® (darifenacin) is a branded prescription medicine in extended release tablet form which is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Micrel, Inc. (NASDAQ: MCRL)
, a leading global manufacturer of IC solutions for the worldwide high performance linear and power, LAN and timing and communications markets, will announce financial results for the fourth quarter and year ended December 31, 2012 after the market closes on Thursday, January 31, 2013.

OncoSec Medical Inc. (OTCBB: ONCS)
, a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the Noble Financial Capital Markets' Ninth Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22 at 12:30 PM Eastern Time.

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)
(the “Company”) today announced that it has priced its private offering of $110 million in aggregate principal amount of its 3.25 percent Convertible Senior Notes due 2019.

Pall Corporation (NYSE:PLL)
today announced that its board of directors declared a quarterly dividend of 25 cents per share.

Parametric Sound Corporation (NASDAQ: PAMT)
in response to yesterday's press release by a New York law firm has been advised that the press release is one of many similar "investigation" announcements by the law firm targeting many companies.

Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX)
, a specialty pharmaceutical company, today announced that it has been approved for listing on the NASDAQ Global Market under the symbol “PTX.”

PharmAthene, Inc. (NYSE MKT: PIP)
, a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Noble Financial Capital Markets Ninth Annual Equity Conference on Tuesday, January 22, 2013 at 9:30 a.m. ET in Room 1 at the Hard Rock Hotel, Hollywood, Florida.

pSivida Corp. (NASDAQ:PSDV)
, a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

In response to the nationwide flu epidemic and customer demand, Rite Aid Corporation (NYSE: RAD) announced today it has obtained more than 400,000 additional seasonal flu shots, which began arriving in stores earlier this week.

announced today that Roche Diagnostics Corporation has been selected to FORTUNE magazine's annual list of the "100 Best Companies to Work For."

SafeCode Drug Technologies Corp. (OTCBB: SAFC)
, a developer of a patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, has signed an agreement with INTOVISION PRODUCT DEVELOPMENT & DESIGN  to manufacturers the world's first voice recognition drug safety application  Prototype.

is a globally-known generic pharmaceutical manufacturer, developer and marketer of a wide range of products serving a broad segment of the therapeutics market.

St. Jude Medical, Inc. (NYSE:STJ)
, a global medical device company, today announced European CE Mark approval of its ViewFlex™ Xtra Intracardiac Echocardiography (ICE) Catheter. Designed for control and maneuverability during complex cardiac ablation procedures, the technology will be on display at the eighteenth annual Boston AF Symposium.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH)
, the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), today announced that Darrell Brookstein, the Company's Executive VP of Corporate Development & Finance will present at "NINE"; Noble Financial Capital Markets' Ninth Annual Equity Conference being held at the Hard Rock Hotel in Hollywood, Florida January 22-23, 2013.

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (FRANKFURT:V3T)
(the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has amended its exclusive agreement with bo pharma BV to distribute Verisante Aura™ in the Nordic countries of Sweden, Norway, Denmark, Finland and Iceland; in addition to Belgium, the Netherlands and Luxemburg ("Benelux").

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus